Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Uncategorized

Highlights from the Week of 15th–22nd September Incyte ( FDA, Approval ) Incyte’s OPZELURA is now the first topical JAK inhibitor approved by the FDA to treat atopic dermatitis in children ages 2 to 11 Johnson and Johnson ( FDA, Approval ) FDA approves SC induction of TREMFYA, the first IL-23 inhibitor with both SC and IV options for UC and CD Merck ( FDA, Approval ) FDA approves KEYTRUDA QLEX, an SC formulation of pembrolizumab with hyaluronidase, for adults across most solid tumor indications KalVista Pharmaceuticals ( EMA, Approval ) KalVista Pharmaceuticals’ EKTERLY has been approved in the EU & Switzerland for acute hereditary angioedema attacks; first oral on-demand HAE therapy All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 15th–22nd September 2025 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 15th–22nd September 2025 in the world of pharma and healthcare! 🗞️👀 Read More »

Nephron Napa Summit 2025 Sep 17,2025 Sep 17 Roche Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of September 17th, 2025 💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of September 17th, 2025 💻 Read More »

Highlights from the Week of 8th-15th September, 2025 VYUHPHARMA Johnson&Johnson FDA approves Johnson & Johnson's INLEXZO to transform bladder cancer treatment (FDA, Approval) croma Fon creators of beauty. Croma-Pharma's Obagi saypha® MagIQ™™ receives FDA approval in the U.S. (FDA, Approval) (EMA, Approval PTX PARTNER HERAPEUTICS EMA approves Partner Therapeutics' IMREPLYS for radiation exposure treatment Neurim PHARMACEUTICALS (Health Canada, Approval Health Canada approves Neurim Pharmaceuticals' Slenyto for insomnia in children with autism spectrum disorder and Smith-Magenis Syndrome Pg 1/2 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 8th–15th September, 2025 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 8th–15th September, 2025 in the world of pharma and healthcare! 🗞️👀 Read More »

Morgan Stanley Annual Global Healthcare Conference Sep 08,2025 To Sep 10,2025 Sep 08 MERCK AstraZeneca Lilly Biogen Takeda BAYER REGENERON Bristol Myers Squibb Sep 09 abbvie teva GSK GILEAD AMGEN Roche VERTEX NOVARTIS Sep 10 Johnson&Johnson Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of September 08th – 10th, 2025 💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of September 08th – 10th, 2025 💻 Read More »

VYUHPHARMA Highlights from the Week of September 01-08, 2025 NANOSCOPE THERAPEUTICS Nanoscope's MCO-010 therapy received FDA RMAT designation and five EMA Orphan designations, accelerating its development for a variety of retinal diseases MENARINI Menarini Group's obicetrapib and a combination therapy with ezetimibe have been accepted for review by the EMA for treating primary hypercholesterolaemia and mixed dyslipidaemia, supported by positive data from Ph3 trials IDEAVA BIOSCIENCES Servier and IDEAYA Biosciences have partnered to commercialize the eye cancer treatment darovasertib outside the US, with IDEAYA receiving a $210 million upfront payment and up to $320 million more in potential milestones (FDA, RMAT Designation, EMA, Orphan Drug Designation) (EMA, MAA) (Partnership) Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of September 1st – 8th, 2025 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of September 1st – 8th, 2025 in the world of pharma and healthcare! 🗞️👀 Read More »

INVESTOR CALENDER OF THE WEEK Sep 03,2025 To Sep 05,2025 Sep 03 Cantor Global Healthcare Conference GILEAD REGENERON Well Fargo Healthcare conference Sep 03 AMGEN VERTEX dorsia Johnson Johnson Jazz Pharmaceuticals Sep 04 MERCK GILEAD REGENERON Sep 05 Lilly Visit our website for more updates | www.vyuhpharma.com All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Sep 03,2025 To Sep 05,2025 💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Sep 03,2025 To Sep 05,2025 💻 Read More »

Vyuhpharma Highlights from the Week of 25th August 2025 to 1st Septmeber 2025 Eisai, Biogen (FDA, Approval) FDA approved LEQEMBI IQLIK for weekly at-home maintenance in early Alzheimer's ahead of October 2025 launch Amgen (FDA, Approval) FDA expanded the approval for REPATHAl to include adults at risk of cardiovascular events from uncontrolled LDL-C without prior heart disease Sanofi (FDA, Approval) Sanofi's WAYRILZ becomes the first FDA-approved BTK inhibitor for persistent or chronic ITP after LUNA 3 success Pfizer, BioNTech (FDA, Approval) Pfizer and BioNTech's COMIRNATY LP.8.1 has been approved by the FDA for adults aged 65 and older, as well as high-risk individuals aged 5 to 64, to prevent severe COVID-19 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 25th August 2025 to 1st September 2025 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 25th August 2025 to 1st September 2025 in the world of pharma and healthcare! 🗞️👀 Read More »

INVESTOR CALENDER OF THE WEEK Aug 26,2025 To Aug 27,2025 Conference, Handelsbanken Life Science Innovation Modeyso Investor Webcast Aug 26 Aug 21 All logos and trademarks remain the intellectual properties of their respective owners

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Aug 26,2025 To Aug 27,2025💻

Uncategorized / YASHASWINI N

📢 Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of Aug 26,2025 To Aug 27,2025💻 Read More »

Highlights from the Week of 18th August, 2025 - 25th August, 2025 VYUHPHARMA IONIS FDA approves lonis's DAWNZERA as first RNA-targeted hereditary angioedema therapy; it shows significant and sustained attack rate reduction, with dosing every 4 or 8 weeks (FDA, Approval) (EC, Approval) Spring Works THERAPEUTICS EU grants marketing authorization to SpringWorks Therapeutics-Merck KGaA's OGSIVEO for adult desmoid tumours (EC, Approval) Madrigal Pharmaceuticals Madrigal receives European Commission approval for REZDIFFRA for MASH with moderate to advanced liver fibrosis (EC, Approval) ADVANZ & Aalvotech PHARMA Advanz Pharma and Alvotech gain European Commission approval for MYNZEPLI biosimilar to Eylea after confirmatory clinical equivalence Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 18th -25th August, 2025 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 18th -25th August, 2025 in the world of pharma and healthcare! 🗞️👀 Read More »

VYUHPHARMA Highlights from the Week of August 11-18, 2025 insmed The landmark FDA approval of BRINSUPRI (brensocatib) becomes first-ever treatment for non-cystic fibrosis bronchiectasis valneva Valneva's chikungunya vaccine receives an updated FDA label; the clinical hold has been lifted for the older adult population Superluminal & Lilly Superluminal Medicines and Eli Lilly partnered to develop small molecule drugs for cardiometabolic diseases and obesity (FDA Approval) (FDA, Clinical hold) Pg 1/3 (Partnership) All logos and trademarks remain the intellectual properties of their respective owners

📢Highlights from the Week of 11th -18th August, 2025 in the world of pharma and healthcare! 🗞️👀

Uncategorized / YASHASWINI N

📢Highlights from the Week of 11th -18th August, 2025 in the world of pharma and healthcare! 🗞️👀 Read More »

← Previous 1 … 5 6 7 … 13 Next →

Search

Recent Posts

True workplace inclusivity means supporting employees with chronic, often invisible conditions. Inflammatory Bowel Disease (IBD) affects millions of professionals worldwide, impacting daily life, energy and productivity.This World IBD Day, let’s advocate for understanding, flexible workplaces, and healthcare support. 💼💜
Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 19,2026 To May 20,2026
Highlights from the Week of 11th May – 18th May in the world of pharma and healthcare!
High blood pressure isn’t just a clinical issue; it’s a productivity and workplace wellness issue. Given that stress is a major contributor to hypertension, the 2026 theme “Controlling Hypertension Together” hits home for leadership teams everywhere. Let’s foster environments where health is as important as the bottom line. 📈❤️
Attention stay up to date with the latest investor calls by checking out our calendar for the week of May 12,2026 To May 14,2026

Recent Comments

No comments to show.

Archives

May 2026
April 2026
March 2026
February 2026
January 2026
December 2025
November 2025
October 2025
September 2025
August 2025
July 2025
June 2025
May 2025
April 2025
March 2025
February 2025
January 2025

Categories

Uncategorized

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message